Article By:
Claus Vistesen
Sunday, February 18, 2024 1:40 PM EDT
We’re currently living in the soft landing, and it is pleasant indeed. But inflation numbers at the start of the year have put us on notice. Like the Magnificent Seven, hopes of a sustained soft landing in the economy are cruising for a bruising.
There Is Beta In Protalix Stock Due To PRX-102
Isn't that made by Sanofi $SNY?
Protalix BioTherapeutics Pipeline Progress
#Protalix clearly has a lot of potential but there's a limited number of people who will need this drug. So the real question is how much of a dent will they put into #Sanofi's market share. $PLX $SNY
Protalix BioTherapeutics Pipeline Progress
My pleasure. What's more important than how prevalent the disease is, is how much money #Protalix can make on its new drug. It's competitor, #Sanofi ($SNY) makes $1 billion in revenue annually on their drug. Protalix's sounds like a more promising alternative. I'd definitely rate $PLX a buy.